Citigroup began coverage on shares of Bruker (NASDAQ:BRKR) in a research note issued to investors on Monday, January 6th, MarketBeat Ratings reports. The firm set a “buy” rating and a $52.00 price target on the medical research company’s stock. Citigroup‘s price objective indicates a potential downside of 3.58% from the company’s current price.
Other analysts also recently issued reports about the stock. Needham & Company LLC started coverage on shares of Bruker in a research report on Friday, January 3rd. They issued a “strong-buy” rating and a $39.00 price objective on the stock. Bank of America upgraded shares of Bruker from a “neutral” rating to a “buy” rating and set a $52.00 price target on the stock in a research report on Thursday, September 26th. Zacks Investment Research downgraded shares of Bruker from a “hold” rating to a “sell” rating and set a $46.00 target price on the stock. in a research report on Tuesday, October 15th. BidaskClub downgraded shares of Bruker from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, ValuEngine raised shares of Bruker from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $50.23.
Shares of Bruker stock traded up $0.05 during trading hours on Monday, reaching $53.93. The company’s stock had a trading volume of 5,946 shares, compared to its average volume of 396,791. The company’s 50 day simple moving average is $50.77 and its 200 day simple moving average is $46.79. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.32 and a current ratio of 2.23. Bruker has a one year low of $33.53 and a one year high of $54.35. The stock has a market cap of $8.23 billion, a P/E ratio of 38.47, a price-to-earnings-growth ratio of 2.32 and a beta of 1.42.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, October 31st. The medical research company reported $0.43 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.05. The firm had revenue of $521.10 million for the quarter, compared to the consensus estimate of $493.52 million. Bruker had a net margin of 10.20% and a return on equity of 28.02%. Bruker’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $0.37 EPS. On average, sell-side analysts predict that Bruker will post 1.63 earnings per share for the current fiscal year.
In other news, Director Marc A. Kastner sold 3,203 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $47.39, for a total value of $151,790.17. Following the sale, the director now owns 7,608 shares of the company’s stock, valued at approximately $360,543.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 26.50% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of BRKR. Calamos Advisors LLC increased its holdings in shares of Bruker by 2.4% during the 4th quarter. Calamos Advisors LLC now owns 11,780 shares of the medical research company’s stock worth $600,000 after buying an additional 280 shares during the last quarter. Rhumbline Advisers increased its holdings in Bruker by 0.4% in the 3rd quarter. Rhumbline Advisers now owns 110,597 shares of the medical research company’s stock valued at $4,859,000 after purchasing an additional 389 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in Bruker by 1.5% in the 3rd quarter. Envestnet Asset Management Inc. now owns 33,270 shares of the medical research company’s stock valued at $1,462,000 after purchasing an additional 476 shares during the last quarter. Jennison Associates LLC increased its holdings in Bruker by 3.6% in the 2nd quarter. Jennison Associates LLC now owns 15,987 shares of the medical research company’s stock valued at $799,000 after purchasing an additional 554 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Bruker by 4.8% in the third quarter. Nisa Investment Advisors LLC now owns 14,990 shares of the medical research company’s stock worth $659,000 after acquiring an additional 692 shares in the last quarter. 68.92% of the stock is owned by institutional investors and hedge funds.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: Penny Stocks
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.